These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26555897)

  • 1. Predictors of Fatigue in Rheumatoid Arthritis Patients in Remission or in a Low Disease Activity State.
    Olsen CL; Lie E; Kvien TK; Zangi HA
    Arthritis Care Res (Hoboken); 2016 Jul; 68(7):1043-8. PubMed ID: 26555897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
    Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
    Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.
    Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatigue in rheumatoid arthritis reflects pain, not disease activity.
    Pollard LC; Choy EH; Gonzalez J; Khoshaba B; Scott DL
    Rheumatology (Oxford); 2006 Jul; 45(7):885-9. PubMed ID: 16449363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis.
    Hammer HB; Michelsen B; Sexton J; Uhlig T; Provan SA
    Clin Rheumatol; 2021 May; 40(5):1739-1749. PubMed ID: 33040226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
    Iwamoto N; Kawakami A; Fujikawa K; Aramaki T; Kawashiri SY; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Goto A; Fukuda T; Matsuoka N; Ueki Y; Tsukada T; Migita K; Shoumura F; Kawabe Y; Shibatomi K; Mine M; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(5):488-92. PubMed ID: 19578932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Number of active joints, not diagnosis, is the primary determinant of function and performance in early synovitis.
    Gerber LH; Furst G; Yarboro C; el-Gabalawy H
    Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S65-70. PubMed ID: 14969053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis.
    Minnock P; Veale DJ; Bresnihan B; FitzGerald O; McKee G
    Clin Rheumatol; 2015 Nov; 34(11):1857-65. PubMed ID: 26453249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.
    Choy T; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE;
    Rheumatology (Oxford); 2014 Mar; 53(3):482-90. PubMed ID: 24241035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to remission in swollen joints is far faster than patient reported outcomes in rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI).
    Pope JE; Rampakakis E; Movahedi M; Cesta A; Sampalis JS; Bombardier C;
    Rheumatology (Oxford); 2021 Feb; 60(2):717-727. PubMed ID: 32789456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of anti-TNF-α vs. DMARDs on fatigue in rheumatoid arthritis patients.
    van Hoogmoed D; Fransen J; Repping-Wuts H; Spee L; Bleijenberg G; van Riel PL
    Scand J Rheumatol; 2013; 42(1):15-9. PubMed ID: 22992002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment.
    Holten K; Paulshus Sundlisater N; Lillegraven S; Sexton J; Nordberg LB; Moholt E; Hammer HB; Uhlig T; Kvien TK; Haavardsholm EA; Aga AB
    Ann Rheum Dis; 2022 Mar; 81(3):344-350. PubMed ID: 34389605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study.
    Perrotta FM; De Socio A; Scriffignano S; Lubrano E
    Clin Rheumatol; 2018 Jun; 37(6):1449-1455. PubMed ID: 29468339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
    Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
    Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years.
    Andersson ML; Svensson B; Bergman S
    J Rheumatol; 2013 Dec; 40(12):1977-85. PubMed ID: 24187108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
    Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
    J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
    Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
    J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.